939768-59-9 Usage
Uses
Due to the limited information available on benzyl 3-(hydroxymethyl)cyclobutanecarboxylate, its applications are not well-documented. However, based on the presence of a carboxylate group and a hydroxymethyl group, it can be inferred that benzyl 3-(hydroxyMethyl)cyclobutanecarboxylate may have potential uses in various industries, such as:
Used in Pharmaceutical Industry:
Benzyl 3-(hydroxymethyl)cyclobutanecarboxylate may be used as an intermediate compound in the synthesis of pharmaceutical drugs. The carboxylate and hydroxymethyl groups could potentially be involved in the formation of new drug molecules with therapeutic properties.
Used in Chemical Synthesis:
In the field of organic chemistry, benzyl 3-(hydroxymethyl)cyclobutanecarboxylate could be used as a building block or a precursor in the synthesis of more complex molecules. Its unique structure may allow for the creation of novel compounds with specific chemical properties.
Used in Material Science:
benzyl 3-(hydroxyMethyl)cyclobutanecarboxylate may also have potential applications in material science, where its unique structure could contribute to the development of new materials with specific properties, such as improved strength, flexibility, or chemical resistance.
Check Digit Verification of cas no
The CAS Registry Mumber 939768-59-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,9,7,6 and 8 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 939768-59:
(8*9)+(7*3)+(6*9)+(5*7)+(4*6)+(3*8)+(2*5)+(1*9)=249
249 % 10 = 9
So 939768-59-9 is a valid CAS Registry Number.
939768-59-9Relevant articles and documents
Nitroxide derivative of ROCK kinase inhibitor
-
Paragraph 0628; 0632; 0635-0636, (2020/06/17)
The invention provides a small molecular compound of a NO donor. The small molecular compound is characterized in that the small molecular compound is a compound shown represented by structural formula I shown in the description, or a stereoisomer, a geometrical isomer, a tautomer, a racemate, a deuterated isotope derivative, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof; and in the formula I, ring A is a substituted or unsubstituted heteroaromatic ring, X is selected from (CH2)n, n is selected from 0, 1, 2 and 3, R is a substituent group of terminal -O-NO2, R is selected from hydrogen, a hydroxyl group, halogen, an amino group, a cyano group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group and a substituted or unsubstituted heteroalkyl group, and R and R are respectively and independently selected from hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted naphthenic base or an amino protecting group, or R and R are connected to form a substituted or unsubstituted cyclic heteroalkyl group. The compound has a high-activity inhibition effect on ROCK kinase.
